Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

Core Viewpoint - Benitec Biopharma Limited (BNTC) has shown a modest gain of 0.2% over the past four weeks, closing at $12.96, with analysts suggesting a potential upside of 83.9% based on a mean price target of $23.83 [1] Price Targets and Analyst Estimates - The mean estimate for BNTC comprises six short-term price targets with a standard deviation of $6.15, indicating variability among analysts; the lowest estimate is $17.00 (31.2% increase), while the highest is $32.00 (146.9% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding BNTC's earnings prospects, as indicated by a positive trend in earnings estimate revisions; the Zacks Consensus Estimate for the current year has increased by 23% over the past month [11][12] - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which further supports the stock's potential upside [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be prudent due to concerns about analysts' biases and the potential for inflated targets [3][8][10]